Evidence map›Paper›PMID 38616742›Full record

ReviewCurrent pharmaceutical biotechnology2025

Nanodelivery Approaches of Phytoactives for Skin Cancers: Current and Future Perspectives.

Evren Algın Yapar, Merve Nur Ozdemir, Meltem Ezgi Durgun, Ozlem Akbal Dagıstan, Simona Cavalu, Yıldız Ozsoy, Murat Kartal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Evren Algın YaparDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.ORCID 0000-0002-6504-4608
Merve Nur OzdemirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.ORCID 0009-0002-3528-9716
Meltem Ezgi DurgunDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Türkiye.ORCID 0000-0001-5724-9809
Ozlem Akbal DagıstanDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.ORCID 0000-0002-6524-3535
Simona CavaluDepartment of Preclinical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Bihor, România.ORCID 0000-0001-7810-8925
Yıldız OzsoyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.ORCID 0000-0002-9110-3704
Murat KartalDepartment of Pharmacognosy, Faculty of Pharmacy, Bezmialem Vakıf University, Istanbul, Türkiye.ORCID 0000-0003-3538-2769
Istanbul University · TRSivas Cumhuriyet Üniversitesi · TRBezmiâlem Vakıf Üniversitesi · TRIstanbul Health and Technology UniversityUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been an increase in skin cancers due to external factors, especially environmental factors, and studies on treatment alternatives have gained importance. Nanomaterials are common, from sunscreen formulas to formulations designed to treat skin cancers at various stages. Using bioactives has multiple effects in treating skin cancers, which provides many advantages. In this regard, many phytochemicals gain importance with their antioxidant, anti-proliferative, anti-inflammatory, antiangiogenic, and analgesic effects. Their delivery with nanocarriers is on the agenda for phytochemicals to gain the targeted stability, effectiveness, and toxicity/safety properties. This review presents types of skin cancers, phytochemicals effective in skin cancers, and their nanocarrier-loaded studies from an up-to-date perspective.

Indexed as

Antineoplastic Agents, PhytogenicNanoparticlesPhytochemicalsSkin NeoplasmsAnimalsDrug Delivery SystemsHumansAntineoplastic Agents, PhytogenicPhytochemicalsmelanomananocarriersnon-melanomapatents on bioactive.Phytochemicalsskin cancer types

Identifiers

PMID38616742
OpenAlexW4394818477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.